Sarepta Delay Due To Misinterpretation, Not Policy Change, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The regulatory agency made it clear to the Duchenne muscular dystrophy community that its message has remained consistent throughout the discussions regarding eteplirsen, despite Sarepta’s comments to the contrary.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.